Dow Component Merck (MRK) To Go Ex-dividend Tomorrow

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading up 39 points (+0.3%) at 15,230 as of Wednesday, Sep 11, 2013, 10:35 a.m. ET. During this time, 101.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 521.1 million. The NYSE advances/declines ratio sits at 1,035 issues advancing vs. 1,794 declining with 126 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Thursday, September 12, 2013 is the ex-dividend date for Dow component Merck (NYSE: MRK). Owners of shares as of market close today will be eligible for a dividend of 43 cents per share. At a price of $48.20 as of 10:35 a.m. ET, the dividend yield is 3.6% compared to the average Dow component yield of 2.7%.

The average volume for Merck has been 11.7 million shares per day over the past 30 days. Merck has a market cap of $139.71 billion and is part of the health care sector and drugs industry. Shares are up 17.2% year to date as of Tuesday's close.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company has a P/E ratio of 28.6, equal to the average drugs industry P/E ratio.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts